25I-NBMD

25I-NBMD
Clinical data
Other names	NBMD-2C-I; Cimbi-29
Legal status
Legal status	DE: NpSG (Industrial and scientific use only); UK: Class A;
Identifiers
	IUPAC name N-[(2H-1,3-benzodioxol-4-yl)methyl]-2-(4-iodo-2,5-dimethoxyphenyl)ethan-1-amine;
CAS Number	919797-25-4 ;
PubChem CID	57507899;
ChemSpider	26234932 ;
UNII	R99110126K;
CompTox Dashboard (EPA)	DTXSID70726967 ;
Chemical and physical data
Formula	C18H20INO4
Molar mass	441.265 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES c13OCOc3cccc1CNCCc(c(OC)cc2I)cc2OC;
	InChI InChI=1S/C18H20INO4/c1-21-16-9-14(19)17(22-2)8-12(16)6-7-20-10-13-4-3-5-15-18(13)24-11-23-15/h3-5,8-9,20H,6-7,10-11H2,1-2H3 ; Key:NJNMIPDEUMTYNV-UHFFFAOYSA-N ;
	(what is this?) (verify)

Other namesNBMD-2C-I; Cimbi-29

Legal status

DE: NpSG (Industrial and scientific use only)
UK: Class A

CAS Number

919797-25-4^N

PubChem CID

57507899

25I-NBMD (NBMD-2C-I, Cimbi-29) is a derivative of the phenethylamine hallucinogen 2C-I, discovered in 2006 by a team at Purdue University led by David Nichols. It acts as a potent partial agonist for the 5HT_2A receptor with a Ki of 0.049 nM at the human 5HT_2A receptor.^[1]^[2]^[3] The corresponding 4-bromo analogue 25B-NBMD has been used for molecular dynamics studies on the shape of the 5-HT_2A receptor.^[4]

[1]

[2]

[3]

[4]

25I-NBMD

Legality

Sweden

United Kingdom

See also

References

Related Articles